Isohelix Scores a Second Chinese CFDA Registration
Isohelix (UK) announces that their range of innovative DNA Buccal Swabs are now registered with the Chinese CFDA, alongside the recently CFDA filed DNA Saliva Collectors. The registration process included rigorous and exhaustive checks, covering risk analysis, manufacturing specifications, technical product performance and quality control processes. Tom Hole, CEO of Isohelix comments that “Isohelix has been well established in the marketplace for some time, and the registration of both of these key product lines supports the quality of our product design, manufacture and ongoing development.”
ISO Certifications Renewed
Cell Projects and Isohelix renew both its ISO9001 and ISO13485 certifications. Following an external renewal audit, we are delighted that Cell Projects/Isohelix passed first time, without any listed non-conformities, attaining the more stringent and latest ISO certifications.
GeneFiX™ receives CE-IVD marking
Isohelix is pleased to announce that its GeneFiX™ Saliva DNA Collection Device has received CE-IVD marking, through completion of a comprehensive technical validation under the European Directive for In Vitro Diagnostic Medical Devices. Read more about this CE-IVD marking. Isohelix is a division of Cell Projects Ltd.
Laboratory expansion for Isohelix
Isohelix are initiating the construction of new cutting-edge laboratory facilities, the first in a series of laboratory redevelopments for the company. The new laboratories will ultimately add value and complement the existing excellent laboratory facilities. Read more information about the expansion here. Isohelix is a division of Cell Projects Ltd.
More saliva devices to choose from within the GeneFiX™ DNA collection
The Isohelix GeneFiX™ DNA collection has been expanded to include ‘Assisted’ and ‘Smaller Volume’ saliva devices. Read more for full product details. Isohelix is a division of Cell Projects Ltd.
New BuccalFix Swab products available enabling improved DNA stabilization
Isohelix is pleased to announce a range of new BuccalFix products available which enable improved DNA stabilization. Available both in pre-aliquoted Manual and HT tubes.
Isohelix is a division of Cell Projects Ltd.
Cell Projects announces the appointment of Geoff Spink as a Non-Executive Director
Geoff has held many CEO and Senior Director positions in UK/International listed private and venture capital-backed companies, many within the Life Sciences sector. Tom Hole, CEO of Cell Projects, said “I am delighted to welcome Geoff to the Board. I know that he will provide valuable assistance as we continue with the strategic development and growth of our business.”
Cell Projects continues to expand its products under the ‘Isohelix brand with the GeneFiX Saliva DNA Collections and Isolation’ products.
Cell Projects extends its Molecular Biology Laboratories due to continued expansion within its Manufacturing, Development and Service businesses.
Two New additional Isohelix DNA Isolation kits have been launched for use with DNA swabs. Both kits have been designed to produce the very highest qualities of DNA.
Isohelix products scale new heights on Mount Everest
Isohelix DNA Swabs and Stabilising Capsules from Cell Projects will be used for repeated DNA sampling and storage on the forthcoming Xtreme Everest 2 Expedition.
Tom Hole, Managing Director at Cell Projects, announces the issue of US Patent no 8222014 for ‘Apparatus and Method for Planar Electroporation’ which is one of many patents supporting a new and unique range of Adherent Cell Electroporation devices being developed and commercialised at Cell Projects.
Cell Projects announces its successful Certification of the ‘ISO 13485:2003’ Quality Management Standard, to a level suitable for the design and manufacture of devices used in In-Vitro diagnostics kits.
Cell Projects presents posters on the Insitu technology at the International Gap Junction Conference 2011 in Ghent, Belgium.
Cell Projects signs an exclusive worldwide agreement with a London NHS Hospital Trust to commercialise patent protected technologies for improving DNA yields from buccal and saliva collection devices.
Cell Projects wins EU research grant to develop Adherent Electroporation as an In Vitro drug testing model for primary heart and cancer cell lines.
Additional Office and Laboratory facilities are built at Cell Projects to cover the rapid expansion of the business.
Cell Projects enters into a wide ranging commercial license and joint development agreement with Queen’s University, Kingston, Ontario, Canada covering key Adherent Cell Electroporation Technologies.
Cell Projects launches expanded range of PCR plates, strips and films.
Cell Projects is awarded BS EN ISO 9001:2000 Quality Certification.
Cell Projects acquires Isohelix, a specialist manufacturer of easy-to-use high-yield DNA buccal swab devices and related isolation kits for the healthcare and life sciences sectors.
Cell Projects introduces a range of cap strips for PCR and QPCR applications.
Cell Projects moves into new purpose designed office, laboratory and warehouse facilities in Harrietsham, UK.
Cell Projects wins DTI financial support under the ‘passport to export’ scheme.
Cell Projects launches a range of branded 96 well PCR plates with improved performance characteristics.
Several OEM and private label manufacturing agreements are agreed for Electroporation and other Molecular Biology consumables.
Cell Projects sets up a new division to handle sub contract development and manufacturing agreements with external corporations.
The Electrobuffer range of kits are introduced, aimed at improving efficiencies and reducing Cell Trauma for Mammalian Cell Electroporation.
Cell Projects completes key International Sales and Marketing Agreements with Specialist Molecular Biology distributors for countries within Europe, America and Far East.
A new range of technically superior Electroporation products are launched.
The Cell Projects Research, Development and Manufacturing facilities are opened.